Vaxcyte Inc

Trading Arrangements

Theadoption, modification ortermination of contracts, instructions or written plans for the purchase or sale of our securities by our Section 16 officers or directors for the three months ended December 31, 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (“10b5-1 Plan”), were as follows:

Peter Hirth, amember of our Board, adopted a 10b5-1 Plan on December 6, 2024, with an effective date of March 7, 2025. Dr. Hirth’s 10b5-1 Plan provides for the potential exercise and sale of up to 13,200 shares of our common stock, and expires on March 31, 2026, or upon the earlier completion of all authorized transactions thereunder.

Grant Pickering, our Chief Executive Officer and a member of our Board, terminated his 10b5-1 Plan on December 31, 2024. Mr. Pickering’s 10b5-1 Plan was originally adopted on April 12, 2024 for the potential sale of (i) up to 45,000 shares of our common stock held by Mr. Pickering and the potential exercise and sale of up to 195,000 shares of our common stock held by Mr. Pickering, and (ii) up to 35,490 shares of our common stock held by trusts in which the beneficiaries are children of Mr. Pickering, until October 1, 2025, or upon the earlier completion of all authorized transactions thereunder.